Attached files

file filename
EX-99.1 - OxySure Therapeutics, Inc.v306202_ex99-1.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported) March 15, 2012


 
OxySure Systems, Inc.
(Exact name of registrant as specified in its chapter)


 
Delaware
(State or other jurisdiction
of incorporation
000-54137
(Commission
File Number)
71-0960725
(IRS Employer
Identification No.)

 

10880 John W. Elliott Drive, Suite 600, Frisco, TX

(Address of principal executive offices)

75033
(Zip Code)


 
   

 

(972) 294-6450

Registrant's telephone number, including area code



 
__________________________________________________________________
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

£Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

£Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

£Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

£Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

 

Section 1 – Registrant’s Business and Operations

 

Item 1.01 – Entry into a Material Definitive Agreement

 

On March 15, 2012, OxySure Systems, Inc. (the “Company”) issued a press release regarding its entry into a supplier agreement with W.W. Grainger, Inc. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information in Item 1.01 of this report, including the press release attached as Exhibit 99.1, is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, such information shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)   Exhibits

 

Exhibit No.   Description
99.1   Press release dated March 15, 2012

 

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  Date: March 15, 2012
   
  OXYSURE SYSTEMS, INC., 
  a Delaware corporation 
   
   
  /s/ Julian T. Ross
  BY:   Julian T. Ross
  ITS:

Chief Executive Officer, President,

    Chief Financial Officer, and Secretary

 

3